Acorda Therapeutics Inc $29.75

down -0.13


22/7/2014 04:00 PM  |  NASDAQ : ACOR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ACOR Trend Analysis - it has underperformed the S&P 500 by 37%

Partner Headlines

  1. Actavis Fuels Growth With Acquisitions, New Generics

    IBD
  2. Markets Edge Higher; Alcoa Profit Beats Street View

    Benzinga
  3. Benzinga's Volume Movers

    Benzinga
  4. Market Wrap For June 17: Markets Higher Ahead Of Fed Decision

    Benzinga
  5. Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session

    Benzinga
  6. Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics ...

    Benzinga
  7. Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Citigroup downgraded Acorda Therapeutics, Says Fundamentals Have Reversed ...

    Benzinga
  10. Acorda Therapeutics Announces European Patent Office Upholds Fampridine ...

    Benzinga
  11. Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of ...

    Benzinga
  12. Acorda Therapeutics Reports Data from Phase 2 Trial of Delfampridine-ER, ...

    Benzinga
  13. Acorda Therapeutics Could Be a Stock to Watch in 2013

    Benzinga
  14. UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, ...

    Benzinga
  15. A Peek Into The Market Before The Trading Starts

    Benzinga
  16. Acorda Therapeutics, Inc. (ACOR) CFO David Lawrence sells 9,313 Shares

    GuruFocus
  17. Acorda Therapeutics, Inc. (ACOR) President and CEO Ron Cohen sells 16,4 ...

    GuruFocus
  18. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  19. Acorda Therapeutics Names Jane Wasman President, International

    Benzinga
  20. UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra ...

    Benzinga
  21. Tesoro, Focus Media Among Stocks Up on High Volume Monday

    FoxBusiness
  22. Benzinga's Top Pre-Market Gainers

    Benzinga
  23. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  24. Health Care Sector Wrap

    FoxBusiness
  25. From Earlier: Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept ...

    Benzinga
  26. A Peek Into The Market Before The Trading Starts

    Benzinga
  27. Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study ...

    Benzinga
  28. UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk

    Benzinga
  29. Acorda Therapeutics Inc. Reports Operating Results (10-K)

    GuruFocus
  30. Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX ...

    Benzinga
  31. 5 Speculative Biotech Stocks to Consider Buying Now

    GuruFocus
  32. JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM

    Benzinga
Trading Center